Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTA vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: ENTA 3 – 2 DMAC (1 Tie) Matrix Metrics: ENTA 4 – 5 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (46.3/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. ENTA trades at $10.79 (44.0x Forward P/E, -90.0% operating margin) versus DMAC at $8.39 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.72β · 97% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTA vs DMAC
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.39
-4.55% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.72β · 97% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (ENTA 3 – 2 DMAC)

Columns: Metric · ENTA · DMAC
1. Valuation Multiples ENTA
Forward P/E 44.0x N/M
Trailing P/E 44.0x N/M
PEG Ratio N/M N/M
EV / Revenue 5.3x N/M
2. Growth & Scale DMAC
Revenue Growth (YoY) -21.6% +0.0%
Earnings Growth (YoY) -66.2% +0.0%
TTM Revenue (USD) $65M N/A
Market Cap $326.2M $503.1M
3. Profitability & Quality DMAC
Gross Margin 100.0% N/A
Operating Margin -90.0% 0.0%
Net Profit Margin -96.9% 0.0%
Return on Equity (ROE) -70.1% -114.6%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$37M -$32M
Cash Flow Margin -56.6% N/A
Net Cash / Leverage $22M Net Debt (0.55x D/E) $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 78.7% (11th %ile) 106.3% (14th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTA (4) vs DMAC (5)
Institutional Metric ENTA DMAC Criterion Row Edge
Market Capitalization
Scale
$326.2M $503.1M Larger Scale DMAC
Trailing P/E Ratio
Valuation
44.0x N/M Lower Multiple ENTA
Forward P/E Ratio
Valuation
44.0x N/M Lower Multiple ENTA
Revenue Growth (YoY)
Growth
-21.6% +0.0% Higher Growth DMAC
Operating Margin (TTM)
Profitability
-90.0% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-96.9% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-70.1% -114.6% Higher ROE ENTA
52-Week Range Position
Momentum
10% ($10–$17) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 1.72β · 97% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$65M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($22M Net Debt (0.55x D/E)) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +13.62 pp
ENTA: -2.79% · DMAC: +10.83%
3M Horizon DMAC +45.8 pp
ENTA: -18.87% · DMAC: +26.93%
6M Horizon DMAC +67.49 pp
ENTA: -19.78% · DMAC: +47.71%
1Y Horizon DMAC +62.74 pp
ENTA: -7.94% · DMAC: +54.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTA Revenue DMAC Revenue ENTA Op. Margin DMAC Op. Margin Margin Leader
FY2018 $210M $0M 42.7% -1352.2% ENTA
FY2019 $210M N/A 17.9% N/A ENTA
FY2020 $120M N/A -34.0% N/A ENTA
FY2021 $100M N/A -112.9% N/A ENTA
FY2022 $90M N/A -143.7% N/A ENTA
FY2023 $80M N/A -173.2% N/A ENTA
FY2024 $70M N/A -179.9% N/A ENTA
FY2025 $70M N/A -130.7% N/A ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTA vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (46.3/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. ENTA trades at $10.79 (44.0x Forward P/E, -90.0% operating margin) versus DMAC at $8.39 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.72β · 97% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTA cumulative revenue shifted -66.7% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

ENTA screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.72β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.